Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 4/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 3/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.65 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | HTR2B | P41595 | 3/20 | 0.65 |
| ▸ | HRH2 | P25021 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cizolirtine SCHEMBL5186750 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| Cizolirtine SCHEMBL2776433 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4910683 | 0.92 | SLC6A2 (0.54) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4902097 | 0.89 | SLC6A2 (0.50) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL5431109 | 0.88 | SLC6A2 (0.49) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4907316 | 0.88 | CHRM2 (0.57) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL19471225 | 0.87 | SLC6A2 (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4909557 | 0.86 | KDM4E (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL5184053 | 0.86 | SLC6A2 (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4907960 | 0.86 | LMNA (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-03 | — | — | US | claimed |
| CN-113226379-A | Nanoparticle encapsulation targeting G protein-coupled receptors in endosomes | 武田药品工业株式会社 | 2021-08-06 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20110212173-A1 | Controlled Release Treatment of Depression | e-Therapeutics Ple (GB) | 2011-09-01 | — | — | US | claimed |
| EP-2315585-A1 | CONTROLLED RELEASE TREATMENT OF DEPRESSION | E-Therapeutics plc (GB) | 2011-05-04 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101801361-A | Treatment of depression | THERAPEUTICS LTD E | 2010-08-11 | — | — | CN | claimed |
| WO-2010004256-A1 | CONTROLLED RELEASE TREATMENT OF DEPRESSION | E-THERAPEUTICS PLC (GB) | 2010-01-14 | — | — | WO | claimed |
| EP-2086641-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| US-6518295-B1 | Such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20030022925-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | LABORATORIOS DEL DR. ESTEVE, S.A. | 2003-01-30 | — | — | US | claimed |
| EP-1029852-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | ESTEVE LABOR DR (ES) | 2002-11-06 | — | — | EP | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1086682-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-28 | — | — | EP | claimed |
| US-6187930-B1 | REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-02-13 | — | — | US | claimed |
| US-6118009-A | Process for obtaining enantiomers of cis-olirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-09-12 | — | — | US | claimed |
| EP-1029852-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-23 | — | — | EP | claimed |
| EP-1024137-A1 | RESOLUTION OF AMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-02 | — | — | EP | claimed |
| EP-0289380-B1 | Aryl-heteroaryl-carbinol derivatives having an analgesic activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031849-A1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | GPR88, GPR65, ARRB1 | SLC6A2 539/4885SLC6A3 625/4885LMNA 3832/4885 |
| US-20030022925-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | AADAC, ABAT, AHR | SLC6A2 1064/4885SLC6A3 1009/4885LMNA 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.